Biopharma & Life Sciences
Elicio Therapeutics Executive Compensation (FY25)
ELTX · Executive and director compensation, fiscal 2023 to 2025
Chief executive, fiscal 2025 ◇ Robert Connelly |
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The paid brief on Elicio Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Data as of October 22, 2026Latest filing (DEF 14A): October 9, 2026
2 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Member, one year
82 figures on this page, cited to the filing that reported them. See the citations
More on Elicio Therapeutics
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Robert Connelly: $2,036,441 → $1,887,660 (7.3% lower)
Frequently asked questions
Answers drawn from the data on this page.
Who is Elicio Therapeutics' chief executive and what were they paid?
Robert Connelly was paid $1,887,660 in total compensation as President, Chief Executive Officer, and Director for fiscal 2025. Connelly's total was 7.3% lower than the $2,036,441 reported for fiscal 2024.
What was Elicio Therapeutics' say-on-pay result?
As an emerging growth company, the company is exempt from the advisory say-on-pay vote.
Which companies are in Elicio Therapeutics' peer group?
The disclosed peer group names Brainstorm Cell Therapeutics, Inc. and Cidara Therapeutics, Inc.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Robert Connelly President, Chief Executive Officer, and Director | ◇ | — | — | — | ◇ | — | — | ◇ |
Christopher Haqq Executive Vice President, Head of Research and Development and Chief Medical Officer | ◇ | — | — | — | ◇ | — | — | ◇ |
Peter DeMuth Chief Scientific Officer | ◇ | — | — | — | ◇ | — | — | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Robert Connelly President, Chief Executive Officer, and Director | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Christopher Haqq Executive Vice President, Head of Research and Development and Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Peter DeMuth Chief Scientific Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Robert Connelly President, Chief Executive Officer, and Director | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
Preetam Shah Chief Strategy and Financial Officer and Treasurer | ◇ | — | — | ◇ | ◇ | — | ◇ | ◇ |
Christopher Haqq Executive Vice President, Head of Research and Development and Chief Medical Officer | ◇ | — | — | ◇ | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Robert Connelly | OPTION | ◇ | — | — | ◇ | — | — | — |
| Robert Connelly | OPTION | ◇ | — | — | ◇ | — | — | — |
Fiscal 2023 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Christopher Haqq | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — | |
| Preetam Shah | Option | ◇ | — | ◇ | — |
| Robert Connelly | Option | ◇ | — | ◇ | — |
| Option | ◇ | — | ◇ | — | |
| Option | ◇ | — | ◇ | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Julian Adams, Ph.D Board chair | ◇ | — | ◇ | — | — | — | ◇ |
Carol Ashe | ◇ | — | ◇ | — | — | — | ◇ |
Karen Wilson | ◇ | — | ◇ | — | — | — | ◇ |
Allen R. Nissenson, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Robert R. Ruffolo Jr., Ph.D | ◇ | — | ◇ | — | — | — | ◇ |
Yekaterina (Katie) Chudnovsky | ◇ | — | ◇ | — | — | — | ◇ |
Jay Venkatesan, M.D | ◇ | — | ◇ | — | — | — | ◇ |
Robert Connelly served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
- Brainstorm Cell Therapeutics, Inc. BSTM
- Cidara Therapeutics, Inc. CDAR
Say-on-pay history
Shareholder support for the compensation program, by year.
This company is an emerging growth company and is exempt from the advisory vote on executive compensation. There is no vote to report.
Chief executive pay ratio
As calculated and reported by the company.
This company is an emerging growth company and is not required to report a pay ratio.
Velarion Pro: every company page, peer tools and exports, one seat
One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Robert Connelly (President, Chief Executive Officer, and Director), FY2025 total compensation $1,887,660 (base salary $632,700) [exec_comp, SEC accession 0001601485-26-000061, filed 2026-10-09]What this page does not include
Everything above is a fact Elicio Therapeutics disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Elicio Therapeutics sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
82 figures on this page, cited to the filing that reported them.
82 cited to the filing
Documents cited
- 0001601485-26-000061Director Compensation · Outstanding Equity Awards at 202 · Summary Compensation Table
- 0001601485-25-0000622024 Summary Compensation Table · TABLE OF CONTENTS EXECUTIVE COMPENSATION
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Elicio Therapeutics executive compensation, FY2023–FY2025.” https://intel.velarion.ai/comp/ELTX (accessed 2026).
Short form: data: Velarion
The paid brief for Elicio Therapeutics
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
2 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Elicio Therapeutics and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Biopharma & Life Sciences rankings
Peers Elicio Therapeutics discloses
The companies named in ELTX's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}